Skip to main content

What the FDA labels say about taking them together

Glecaprevir/pibrentasvir and ritonavir

Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names ritonavir in its drug interactions section, and ritonavir's label names glecaprevir/pibrentasvir too. The glecaprevir/pibrentasvir label: “Coadministration is not recommended.”

Check it at the source: the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).

What does the glecaprevir/pibrentasvir label say about ritonavir?

Glecaprevir/pibrentasvir label, drug interactions

Concomitant Drug Class/Drug Name: Darunavir Lopinavir Ritonavir; Effect on Concentration: ↑ glecaprevir ↑ pibrentasvir; Clinical Comments: Coadministration is not recommended.

Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed

What does the ritonavir label say about glecaprevir/pibrentasvir?

Ritonavir label, drug interactions

Hepatitis C direct acting antiviral: glecaprevir/pibrentasvir simeprevir ↑ glecaprevir ↑ pibrentasvir ↑simeprevir It is not recommended to co-administer ritonavir with glecaprevir/pibrentasvir, or simeprevir.

Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Glecaprevir/pibrentasvir generic labelers
7Ritonavir generic labelers
Glecaprevir/pibrentasvirRitonavir
Labeled forHepatitis CHIV
Boxed warningYesYes
Pharmacy cost (NADAC)$152.98 per tablet 100-40 mg tablet$0.607 per tablet 100 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?